Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
TOKYO and SHANGHAI, Feb. 5, 2026 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Shanghai Henlius Biotech, Inc. (Headquarters: Shanghai, China, CEO: Jason Zhu, "Henlius") announced today the conclusion of an exclusive commercialization and co-exclusive development and manufacturing license agreement for the anti-PD-1 antibody serplulimab (generic name, marketed as HANSIZHUANG in China and Hetronifly® in the EU) in Japan. Serplulimab, a novel anti-PD-1...
HanchorBio Accelerates Global Clinical Footprint with Multiple Oral and Poster Presentations in Q1 2026
Sustained execution and high-impact data across HanchorBio's next-generation immuno-oncology portfolio to be featured at ASCO-GI, AACR-IO, ESMO-TAT, ICNHO, and WOC TAIPEI and SHANGHAI and SAN FRANCISCO, Feb. 4, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company pioneering transformative immunotherapies, today announced a robust schedule of scientific presentations at major international oncology congresses throughout Q1...
Galaxy Brain Scientific’s Technology Enables Landmark Parkinson’s Study Published in Nature, Redefining Disease Mechanism
BEIJING, Feb. 5, 2026 /PRNewswire/ -- A research team led by Prof. Hesheng Liu, founder and Chief Scientific Officer of Galaxy Brain Scientific Inc., has published a study in Nature that pinpoints the core functional circuit underlying Parkinson's disease (PD). The findings redefine the biological mechanism of PD and provide a scientific basis for developing precision neural circuit stimulation...
Moleac is pleased to announce that NeuroAiD™II has been awarded Gold accreditation by Empowered By Evidence.
SINGAPORE, Feb. 5, 2026 /PRNewswire/ -- This recognition reflects the robust clinical evidence supporting NeuroAiD™II, as well as the uniqueness of its formulation, the rigour of its manufacturing, reproducibility, and quality control, highlighting its reliability and value in supporting neurological disorders. Empowered By Evidence (EBE) is an independent, international non-profit organisation, founded in 2014 and based in New York....
Asian Smart Medical Online Exhibition 2026: Connecting Smart Medical Suppliers with Global Buyers
TAIPEI, Feb. 5, 2026 /PRNewswire/ -- The Asian Smart Medical Online Exhibition 2026 (Medical Asia 2026) is a premier hybrid exhibition designed to seamlessly connect Asian medical suppliers, importers, and exporters with buyers from around the world. Taking place from February 3, 2026, to May 31, 2026, Medical Asia 2026, this four-month online exhibition provides exhibitors with an exceptional...
Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013
SHANGHAI, Feb. 5, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an exclusive license agreement with Shaanxi Micot Pharmaceutical Technology Co., Ltd. ("Micot") to commercialize MT1013, the world's first-in-class dual-targeting receptor agonist polypeptide that...
Finally, a Natural Alternative to Acacia Gum in Beverages
RIVER FALLS, Wis., Feb. 5, 2026 /PRNewswire/ -- Fiberstar, Inc., the leader of innovative citrus fibers launched an all-natural alternative to acacia gum – Citri-Fi® Pro. For decades, the beverage industry has been searching for an acacia gum replacement due to the geopolitical instability in the Sudan region which is causing humanitarian crises thus...
Yuyu Pharma Invests in James & Ella, Advancing Its Global Expansion Into Premium Pet Wellness
SEOUL, South Korea, Feb. 4, 2026 /PRNewswire/ -- Yuyu Pharma announced today a strategic investment in James & Ella, the United Kingdom's fastest-growing freeze-dried pet nutrition company. Founded by entrepreneur James Middleton, James & Ella has rapidly established itself as the leader of the UK freeze-dried category, with nationwide distribution through Sainsbury's,...
NYSE Content Update: Disney Names New CEO After Ringing Bell on Main Street USA
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Feb. 4, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Veradermics...
Providence Therapeutics Announces World-First Personalized Pediatric mRNA Cancer Vaccine Trial
Landmark Australian study opens new possibilities for children with aggressive brain tumors and signals opportunity for Canada and USA. CALGARY, AB and BRISBANE, Australia , Feb. 5, 2026 /PRNewswire/ -- Providence Therapeutics, a Canadian clinical-stage mRNA biotechnology company, is supporting a world-first clinical trial evaluating personalized mRNA cancer vaccines for children with advanced and treatment-resistant brain tumors. The PaedNEO-VAX trial, funded by Providence...
